Other movers include Incyte, Achillion and Inovio.
The company paid $4 million up front for the licensing rights for Eyegate's drop device.
The company discusses potential share repurchases and its acquisition strategy.
Gilead (finally!) has acquired something from Sarepta, even if it is quite small.
Healthcare giant Aetna announced a share buyback program Friday.
AstraZeneca shares, meanwhile, were less-than-moved by the news.
Analysts say the stock depression caused by a lawsuit filed by a former United Healthcare executive could be a reason to buy the stock.
In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.
The New Jersey-based animal health company reported better-than-expected fourth quarter earnings Thursday, but shares fell 5%.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.